Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation

Value in Health - United Kingdom
doi 10.1016/j.jval.2019.09.2747
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Preclinical Evaluation of a Novel Non-Invasive Epicutaneous Vaccine Against Respiratory Syncytial Virus

Journal of Allergy and Clinical Immunology
AllergyImmunology
2017English

Patient-Reported Outcomes in a Phase II Study of Alectinib

ESMO Open
Cancer ResearchOncology
2018English

A Respiratory Syncytial Virus-Like Particle Vaccine Shows Promise

Microbe
Microbiology
2016English

Pin129 - Adapting Influenza Patient-Reported Outcomes (Pro) Measures to Monitor Respiratory Syncytial Virus (Rsv) Symptom Severity in Adults: Qualitative Evidence of Key Concepts and Content Validity

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Respiratory Syncytial Virus: Reverse Genetics and Vaccine Strategies

Virology
Virology
2002English

Respiratory Syncytial Virus Infection: Clinical and Laboratory Features

CHILDREN INFECTIONS
2017English

A Feasibility Study of a Social Robot Collecting Patient Reported Outcome Measurements From Older Adults

International Journal of Social Robotics
Computer Science
2019English

Correction for Kim Et Al., Development of an Adenovirus-Based Respiratory Syncytial Virus Vaccine: Preclinical Evaluation of Efficacy, Immunogenicity, and Enhanced Disease in a Cotton Rat Model

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
2015English

Patient‐Reported Comorbidity and Survival in Older Adults With Cancer

Oncologist
Cancer ResearchMedicineOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy